A Phase 2b clinical trial testing NP-120 (ifenprodil) as a treatment for chronic cough is expected to begin later this…
Articles by Marisa Wexler, MS
Treatment with an extract of scorpion venom eased lung scarring in a mouse model of pulmonary fibrosis (PF), a…
Pliant Therapeutics’ experimental oral anti-fibrotic therapy bexotegrast has received orphan drug designation from the European Medicines Agency (EMA) as…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ifenprodil, the active agent in NP-120, an…
Dosing has begun in healthy volunteers in a Phase 1 clinical trial evaluating the safety and pharmacological properties of LASN01,…
Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line…
The oral anti-fibrotic treatment Ofev (nintedanib) was found to be generally well-tolerated among children and adolescents with fibrosing interstitial…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EI-1071, an oral anti-inflammatory that Elixiron Immunotherapeutics…
The U.S. Food and Drug Administration (FDA) has given fast-track designation to DWN12088, an experimental anti-fibrotic medication that Daewoong…
Most idiopathic pulmonary fibrosis (IPF) patients treated with NP-120 (ifenprodil) in a 12-week clinical trial saw their lung function improve…